Active Biotech AB (publ)

DB:BTPC Stock Report

Market Cap: €26.7m

Active Biotech Management

Management criteria checks 4/4

Active Biotech's CEO is Helen Tuvesson, appointed in Jul 2017, has a tenure of 7.33 years. total yearly compensation is SEK4.05M, comprised of 56% salary and 44% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth €8.39K. The average tenure of the management team and the board of directors is 7.3 years and 5.5 years respectively.

Key information

Helen Tuvesson

Chief executive officer

SEK 4.0m

Total compensation

CEO salary percentage56.0%
CEO tenure7.3yrs
CEO ownership0.03%
Management average tenure7.3yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Tuvesson's remuneration changed compared to Active Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 42m

Jun 30 2024n/an/a

-SEK 44m

Mar 31 2024n/an/a

-SEK 45m

Dec 31 2023SEK 4mSEK 2m

-SEK 46m

Sep 30 2023n/an/a

-SEK 48m

Jun 30 2023n/an/a

-SEK 51m

Mar 31 2023n/an/a

-SEK 54m

Dec 31 2022SEK 4mSEK 2m

-SEK 58m

Sep 30 2022n/an/a

-SEK 60m

Jun 30 2022n/an/a

-SEK 57m

Mar 31 2022n/an/a

-SEK 56m

Dec 31 2021SEK 4mSEK 2m

-SEK 50m

Sep 30 2021n/an/a

-SEK 38m

Jun 30 2021n/an/a

-SEK 35m

Mar 31 2021n/an/a

-SEK 32m

Dec 31 2020SEK 3mSEK 2m

-SEK 32m

Sep 30 2020n/an/a

-SEK 39m

Jun 30 2020n/an/a

-SEK 40m

Mar 31 2020n/an/a

-SEK 36m

Dec 31 2019SEK 3mSEK 2m

-SEK 34m

Sep 30 2019n/an/a

-SEK 32m

Jun 30 2019n/an/a

-SEK 31m

Mar 31 2019n/an/a

-SEK 35m

Dec 31 2018SEK 3mSEK 1m

-SEK 37m

Sep 30 2018n/an/a

-SEK 88m

Jun 30 2018n/an/a

-SEK 88m

Mar 31 2018n/an/a

-SEK 103m

Dec 31 2017SEK 2mSEK 1m

-SEK 109m

Compensation vs Market: Helen's total compensation ($USD366.29K) is about average for companies of similar size in the German market ($USD471.14K).

Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.

CEO

Helen Tuvesson (62 yo)

7.3yrs

Tenure

SEK 4,045,000

Compensation

Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...

Leadership Team

NamePositionTenureCompensationOwnership
Helen Tuvesson
President & CEO7.3yrsSEK 4.05m0.031%
€ 8.4k
Hans Kolam
Chief Financial Officer24.8yrsno data0.023%
€ 6.2k
Erik Vahtola
Chief Medical Officer2.8yrsno data0.011%
€ 3.0k

7.3yrs

Average Tenure

62yo

Average Age

Experienced Management: BTPC's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Thelin
Independent Director13.5yrsSEK 206.00kno data
Uli Hacksell
Independent Director5.5yrsSEK 202.00k0.0017%
€ 457.3
Michael Shalmi
Independent Chairman of the Board5.5yrsSEK 524.00k0.049%
€ 13.1k
Axel Glasmacher
Independent Director4.5yrsSEK 203.00k0.0032%
€ 869.2
Aleksandar Danilovski
Independent Director4.5yrsSEK 207.00k0.015%
€ 4.1k

5.5yrs

Average Tenure

64yo

Average Age

Experienced Board: BTPC's board of directors are considered experienced (5.5 years average tenure).